東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"MEDICAL- Diseases." ]

切換: 標籤 | MARC模式 | ISBD

Immune checkpoint inhibitors in cancer

Ito, Fumito,

FindBook

Google Book

Amazon

博客來

Immune checkpoint inhibitors in cancer

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Immune checkpoint inhibitors in cancer/ Fumito Ito, Marc S. Ernstoff.
其他作者:	Ito, Fumito,
出版者:	St. Louis, Missouri :Elsevier, : 2019.,
面頁冊數:	1 online resource.
內容註:	Intro; Title page; Table of Contents; Copyright; Dedication; List of Contributors; Preface; Chapter 1. Immune Checkpoint Inhibitors: Mechanisms and Emerging Therapeutic Opportunities; Introduction; Immune Checkpoint Inhibition: Molecules and Mechanisms; Regulation of the Immune Checkpoint Molecules on Activated T Cells; Regulation of the Expression of Immune Checkpoint Ligands; Factors Affecting the Anti tumor Effectiveness of Immune Checkpoint Inhibitors; Targeting the Tumor Microenvironment to Enhance the Therapeutic Effectiveness of Immune Checkpoint Inhibitors; Conclusions
內容註:	Chapter 2. Immune Checkpoints: Melanoma and Other Skin Cancers melanoma; Background; Ipilimumab (Anti-CTLA-4 Antibody); PD-1 Blockade; Special Considerations With the Use of Immune Checkpoint Inhibitor; Duration of Treatment; The Use of Immune Checkpoint Inhibitors in Specific Populations; Immune Checkpoint Inhibitors for Adjuvant Therapy; Biomarkers for Immune Checkpoint Inhibitor Response; Mechanisms of Resistance; Novel Immune Checkpoint Inhibitors and Combinationsin Development; Conclusion; Merkel Cell Carcinoma; Immunotherapy of Merkel Cell Carcinoma; Conclusion; Conclusion
內容註:	Chapter 3. The Current Status of Immunotherapy in Thoracic Malignancies Introduction; Immune Checkpoint Inhibition; Non-Small-Cell Lung Cancer; Biomarkers of Response or Resistance to Immune Checkpoint Inhibitor Therapy; Future Directions; Combination Therapy With Other Immunotherapy; Non-Small-Cell Lung Cancer; Individualized Tumor Neoantigen-Based Vaccines; Conclusion; Chapter 4. Immune Checkpoint Inhibitors in Gastrointestinal Malignancies; Introduction; Gastroesophageal Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Anal Cancer
內容註:	Patient Selection for Immunotherapy and Biomarker Development summary/Conclusion; Chapter 5. Cancers of the Head and Neck; Introduction; Molecular Biology of Head and Neck Cancers; Immune Escape in Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Salivary Glands Cancer; Conclusion; Chapter 6. Urologic Malignancies; Kidney Cancer; Background: Prior Immunotherapies in Renal Cell Carcinoma; Single-Agent Immune Checkpoint Inhibitors; Combination or ICI-VEGFi; Bladder Cancer; PD-L1-Targeted Agents; PD-L1-Targeted Agents; CTLA-4-Targeted Agents; Other Agents
內容註:	Prostate Cancer Chapter 7. Gynecologic Malignancies; Introduction; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Future Directions; Chapter 8. Breast Cancer; Introduction; Mutational Burden/Tumor-Associated Antigens in BreastCancer; Significance of Tumor-Infiltrating Lymphocytes in Breast Cancer; Programmed Death-Ligand 1 [PD-L1] PD-L1 Expression in Breast Cancer; PD-L1 and PD-1 Inhibitor Studies in Metastatic Breast Cancer; Neoadjuvant Breast Studies; Conclusion; Chapter 9. Hematologic Malignancies; Introduction; Immune Checkpoint Pathway Dysregulation in Hematologic Malignancies
標題:	Cancer - Immunological aspects. -
電子資源:	https://www.sciencedirect.com/science/book/9780323549486
ISBN:	9780323549509 (electronic bk.)

Immune checkpoint inhibitors in cancer
Immune checkpoint inhibitors in cancer[electronic resource] /Fumito Ito, Marc S. Ernstoff. - St. Louis, Missouri :Elsevier,2019. - 1 online resource.

Includes bibliographical references and index.

Intro; Title page; Table of Contents; Copyright; Dedication; List of Contributors; Preface; Chapter 1. Immune Checkpoint Inhibitors: Mechanisms and Emerging Therapeutic Opportunities; Introduction; Immune Checkpoint Inhibition: Molecules and Mechanisms; Regulation of the Immune Checkpoint Molecules on Activated T Cells; Regulation of the Expression of Immune Checkpoint Ligands; Factors Affecting the Anti tumor Effectiveness of Immune Checkpoint Inhibitors; Targeting the Tumor Microenvironment to Enhance the Therapeutic Effectiveness of Immune Checkpoint Inhibitors; Conclusions

ISBN: 9780323549509 (electronic bk.)Subjects--Topical Terms:

658008
Cancer
--Immunological aspects.Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RC268.3 / .I66 2019

Dewey Class. No.: 616.99/4079

National Library of Medicine Call No.: QZ 200

Immune checkpoint inhibitors in cancer
LDR:04008cmm a2200313 a 4500 001 2246314
006 m o d
007 cr cnu---unuuu
008 211223s2019 moua gob 001 0 eng d
020 $a 9780323549509 (electronic bk.)
020 $a 0323549500 (electronic bk.)
020 $a 9780323549486
020 $a 0323549489
035 $a (OCoLC)1050869819
035 $a on1050869819
040 $a OPELS $b eng $c OPELS $d OCLCF $d DKU $d MERER $d EBLCP $d NLE $d YDX $d N$T $d YDX $d OCLCO $d OTZ $d U3W $d OCLCA $d OCLCQ $d LVT $d OCLCO $d OCLCA $d OCLCQ $d D6H $d OCLCO $d OCLCQ $d OCLCA $d OCLCQ $d S2H $d OCLCO $d VT2
041 0 $a eng
050 4 $a RC268.3 $b .I66 2019
060 4 $a QZ 200
082 0 4 $a 616.99/4079 $2 23
245 0 0 $a Immune checkpoint inhibitors in cancer $h [electronic resource] / $c Fumito Ito, Marc S. Ernstoff.
260 $a St. Louis, Missouri : $b Elsevier, $c 2019.
300 $a 1 online resource.
504 $a Includes bibliographical references and index.
505 0 $a Intro; Title page; Table of Contents; Copyright; Dedication; List of Contributors; Preface; Chapter 1. Immune Checkpoint Inhibitors: Mechanisms and Emerging Therapeutic Opportunities; Introduction; Immune Checkpoint Inhibition: Molecules and Mechanisms; Regulation of the Immune Checkpoint Molecules on Activated T Cells; Regulation of the Expression of Immune Checkpoint Ligands; Factors Affecting the Anti tumor Effectiveness of Immune Checkpoint Inhibitors; Targeting the Tumor Microenvironment to Enhance the Therapeutic Effectiveness of Immune Checkpoint Inhibitors; Conclusions
505 8 $a Chapter 2. Immune Checkpoints: Melanoma and Other Skin Cancers melanoma; Background; Ipilimumab (Anti-CTLA-4 Antibody); PD-1 Blockade; Special Considerations With the Use of Immune Checkpoint Inhibitor; Duration of Treatment; The Use of Immune Checkpoint Inhibitors in Specific Populations; Immune Checkpoint Inhibitors for Adjuvant Therapy; Biomarkers for Immune Checkpoint Inhibitor Response; Mechanisms of Resistance; Novel Immune Checkpoint Inhibitors and Combinationsin Development; Conclusion; Merkel Cell Carcinoma; Immunotherapy of Merkel Cell Carcinoma; Conclusion; Conclusion
505 8 $a Chapter 3. The Current Status of Immunotherapy in Thoracic Malignancies Introduction; Immune Checkpoint Inhibition; Non-Small-Cell Lung Cancer; Biomarkers of Response or Resistance to Immune Checkpoint Inhibitor Therapy; Future Directions; Combination Therapy With Other Immunotherapy; Non-Small-Cell Lung Cancer; Individualized Tumor Neoantigen-Based Vaccines; Conclusion; Chapter 4. Immune Checkpoint Inhibitors in Gastrointestinal Malignancies; Introduction; Gastroesophageal Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Anal Cancer
505 8 $a Patient Selection for Immunotherapy and Biomarker Development summary/Conclusion; Chapter 5. Cancers of the Head and Neck; Introduction; Molecular Biology of Head and Neck Cancers; Immune Escape in Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Salivary Glands Cancer; Conclusion; Chapter 6. Urologic Malignancies; Kidney Cancer; Background: Prior Immunotherapies in Renal Cell Carcinoma; Single-Agent Immune Checkpoint Inhibitors; Combination or ICI-VEGFi; Bladder Cancer; PD-L1-Targeted Agents; PD-L1-Targeted Agents; CTLA-4-Targeted Agents; Other Agents
505 8 $a Prostate Cancer Chapter 7. Gynecologic Malignancies; Introduction; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Future Directions; Chapter 8. Breast Cancer; Introduction; Mutational Burden/Tumor-Associated Antigens in BreastCancer; Significance of Tumor-Infiltrating Lymphocytes in Breast Cancer; Programmed Death-Ligand 1 [PD-L1] PD-L1 Expression in Breast Cancer; PD-L1 and PD-1 Inhibitor Studies in Metastatic Breast Cancer; Neoadjuvant Breast Studies; Conclusion; Chapter 9. Hematologic Malignancies; Introduction; Immune Checkpoint Pathway Dysregulation in Hematologic Malignancies
650 0 $a Cancer $x Immunological aspects. $3 658008
650 2 $a Neoplasms $x immunology. $3 833001
650 7 $a HEALTH & FITNESS $x Diseases $x General. $2 bisacsh $3 1614811
650 7 $a MEDICAL $x Clinical Medicine. $2 bisacsh $3 1457888
650 7 $a MEDICAL $x Diseases. $2 bisacsh $3 1614812
650 7 $a MEDICAL $x Evidence-Based Medicine. $2 bisacsh $3 1615052
650 7 $a MEDICAL $x Internal Medicine. $2 bisacsh $3 1615053
655 0 $a Electronic books. $2 lcsh $3 542853
700 1 $a Ito, Fumito, $e editor. $3 3509657
700 1 $a Ernstoff, Marc S., $e editor. $3 3509658
856 4 0 $u https://www.sciencedirect.com/science/book/9780323549486